Targeting mutant estrogen receptors

por Wardell, Suzanne E, Norris, John D, McDonnell, Donald P
Publicado 2019

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer

por Russell, Shonagh, Lim, Felicia, Peters, Pamela N., Wardell, Suzanne E., Whitaker, Regina, Chang, Ching-Yi, Previs, Rebecca A., McDonnell, Donald P.
Publicado 2022

Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors

por Anderson, Gray R., Wardell, Suzanne E., Cakir, Merve, Yip, Catherine, Ahn, Yeong-ran, Ali, Moiez, Yllanes, Alexander P., Chao, Christina A., McDonnell, Donald P., Wood, Kris C.
Publicado 2018

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumo...

por Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P.
Publicado 2019

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activ...

por Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P.
Publicado 2019

ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1

por Mayro, Benjamin, Hoj, Jacob P., Cerda-Smith, Christian G., Hutchinson, Haley M., Caminear, Michael W., Thrash, Hannah L., Winter, Peter S., Wardell, Suzanne E., McDonnell, Donald P., Wu, Colleen, Wood, Kris C., Pendergast, Ann Marie
Publicado 2023

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models

por Manzari, Mandana T., Anderson, Grace R., Lin, Kevin H., Soderquist, Ryan S., Çakir, Merve, Zhang, Mitchell, Moore, Chandler E., Skelton, Rachel N., Fèvre, Maréva, Li, Xinghai, Bellucci, Joseph J., Wardell, Suzanne E., Costa, Simone A., Wood, Kris C., Chilkoti, Ashutosh
Publicado 2019

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

por Pollock, Julie A., Wardell, Suzanne E., Parent, Alexander A., Stagg, David B., Ellison, Stephanie J., Alley, Holly M., Chao, Christina A., Lawrence, Scott A., Stice, James P., Spasojevic, Ivan, Baker, Jennifer G., Kim, Sung Hoon, McDonnell, Donald P., Katzenellenbogen, John A., Norris, John D.
Publicado 2016

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells

por Baek, Amy E., Yu, Yen-Rei A., He, Sisi, Wardell, Suzanne E., Chang, Ching-Yi, Kwon, Sanghoon, Pillai, Ruchita V., McDowell, Hannah B., Thompson, J. Will, Dubois, Laura G., Sullivan, Patrick M., Kemper, Jongsook K., Gunn, Michael D., McDonnell, Donald P., Nelson, Erik R.
Publicado 2017

Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

por Joh, Daniel Y., Heggestad, Jacob T., Zhang, Shengwei, Anderson, Gray R., Bhattacharyya, Jayanta, Wardell, Suzanne E., Wall, Simone A., Cheng, Amy B., Albarghouthi, Faris, Liu, Jason, Oshima, Sachi, Hucknall, Angus M., Hyslop, Terry, Hall, Allison H. S., Wood, Kris C., Shelley Hwang, E., Strickland, Kyle C., Wei, Qingshan, Chilkoti, Ashutosh
Publicado 2021

Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates

por Joh, Daniel Y., Heggestad, Jacob T., Zhang, Shengwei, Anderson, Gray R., Bhattacharyya, Jayanta, Wardell, Suzanne E., Wall, Simone A., Cheng, Amy B., Albarghouthi, Faris, Liu, Jason, Oshima, Sachi, Hucknall, Angus M., Hyslop, Terry, Hall, Allison H. S., Wood, Kris C., Shelley Hwang, E., Strickland, Kyle C., Wei, Qingshan, Chilkoti, Ashutosh
Publicado 2021

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

por Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Publicado 2020